Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Keytruda in NSCLC, Melanoma, and CRC
NCT02437136Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in non-small cell lung cancer (NSCLC), melanoma, colorectal cancer (CRC), sponsored by Syndax Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
entinostat
03
Conditions
non-small cell lung cancer (NSCLC)melanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02437136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437136.